Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
27 avr. 2022 16h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
29 mars 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
02 mars 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
01 mars 2022 08h00 HE
|
Candel Therapeutics
Additional capital extends cash runway into Q4 of 2023 NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the “Company” or “Candel”), a late clinical stage...
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
03 févr. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics to Present at Two Upcoming Investor Conferences
05 janv. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies
15 déc. 2021 05h00 HE
|
Candel Therapeutics
Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors LOS ANGELES and NEEDHAM, Mass., Dec. ...
Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409
10 déc. 2021 08h00 HE
|
Candel Therapeutics
Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancerTrial combines CAN-2409 with immune checkpoint...
Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma
12 nov. 2021 08h00 HE
|
Candel Therapeutics
Data presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual MeetingIntra-tumoral administration of CAN-3110 elicited significant T-cell infiltration and expansion of T-cell...
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
12 nov. 2021 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic...